aston.martin schreef op 15 juli 2015 07:43:
Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research
Galapagos NV
Mechelen, Belgium; 15 July 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for pre-clinical research in cystic fibrosis (CF) and inflammatory bowel disease (IBD).
Organoids are mini-organs grown in cell culture from biopsies taken from patients; these mini-organs faithfully recapitulate the genetic and phenotypic characteristics of diseased tissues. Organoids have proven to be valuable disease models for the high-throughput screening and validation of innovative medicines, bypassing limitations associated with cell-line and xenograft-based pre-clinical drug studies.
Onno van de Stolpe, CEO of Galapagos, said: "The HUB`s Organoid Technology will add an exciting and cutting edge approach to Galapagos` arsenal of research methods and potentially accelerate the discovery and development of our innovative drugs for CF and IBD."
"We are pleased that the HUB and Galapagos have entered into this license agreement", said Dr. Hans Clevers Board Member of the HUB. "This partnership underpins the unique contribution of Organoid Technology to the development of drugs for patients with unmet medical needs, including patients with CF and IBD."
Zo, en nu weten we meteen dat niet alle nieuws na sluiting Nasdaq hoeft gebracht te worden, maar ook net voor opening Europa kan gebracht worden. (voor opening Europa is natuurlijk ook na sluiting Nasdaq :), het is maar hoe je het bekijkt)